FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2237608905> ?p ?o ?g. }

• W2237608905 endingPage "888" @default.
• W2237608905 startingPage "879" @default.
• W2237608905 abstract "Survival rates for elderly Hodgkin Lymphoma (HL) have not improved substantially in recent years, mainly because of a lack of prospective randomized studies, due to difficulties in enrolling patients. Between 2002 and 2006, 54 untreated HL patients, aged between 65 and 80 years and considered ‘non-frail’ according to a comprehensive geriatric evaluation, were enrolled into a phase III randomized trial to compare a reduced-intensity regimen (vinblastine, cyclophosphamide, procarbazine, prednisone, etoposide, mitoxantrone, bleomycin; VEPEMB) with standard ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Primary endpoint was progression-free survival (PFS). Seventeen patients were in early stage (I-IIA), while 37 were advanced stage. Median age was 72 years and median follow-up was 76 months. Five-year PFS rates were 48% vs. 70% [adjusted Hazard ratio (HR) = 2·19, 95% confidence interval (CI) = 0·94–5·10, P = 0·068] and 5-year overall survival (OS) rates were 63% vs. 77% (adjusted HR = 1·67, 95% CI = 0·69–4·03, P = 0·254) for VEPEMB compared to ABVD. Overall treatment-related mortality was 4%. World Health Organization grade 4 cardiac and lung toxicity occurred in four patients treated with ABVD versus no cases in the VEPEMB arm. Standard ABVD regimen resulted in better PFS and OS than the VEPEMB, although the differences were not statistically significant. The low toxicity of both treatments was probably attributable to stringent selection of patients based on a Comprehensive Geriatric Assessment that excluded frail patients." @default.
• W2237608905 created "2016-06-24" @default.
• W2237608905 creator A5016819589 @default.
• W2237608905 creator A5022006811 @default.
• W2237608905 creator A5025882756 @default.
• W2237608905 creator A5028386622 @default.
• W2237608905 creator A5046680192 @default.
• W2237608905 creator A5046704362 @default.
• W2237608905 creator A5047971271 @default.
• W2237608905 creator A5048088301 @default.
• W2237608905 creator A5049017377 @default.
• W2237608905 creator A5058392949 @default.
• W2237608905 creator A5066201212 @default.
• W2237608905 creator A5066452460 @default.
• W2237608905 creator A5069571388 @default.
• W2237608905 creator A5069596141 @default.
• W2237608905 creator A5071466957 @default.
• W2237608905 creator A5076114231 @default.
• W2237608905 creator A5078492047 @default.
• W2237608905 date "2016-01-13" @default.
• W2237608905 modified "2023-10-16" @default.
• W2237608905 title "Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)" @default.
• W2237608905 cites W1967974729 @default.
• W2237608905 cites W1975834243 @default.
• W2237608905 cites W1977273659 @default.
• W2237608905 cites W1978296090 @default.
• W2237608905 cites W1979231328 @default.
• W2237608905 cites W1982377326 @default.
• W2237608905 cites W1992058067 @default.
• W2237608905 cites W2018849750 @default.
• W2237608905 cites W2031593269 @default.
• W2237608905 cites W2038813680 @default.
• W2237608905 cites W2056072361 @default.
• W2237608905 cites W2086060360 @default.
• W2237608905 cites W2093679650 @default.
• W2237608905 cites W2104818042 @default.
• W2237608905 cites W2110635832 @default.
• W2237608905 cites W2133201432 @default.
• W2237608905 cites W2134518458 @default.
• W2237608905 cites W2148999297 @default.
• W2237608905 cites W2153280042 @default.
• W2237608905 cites W2155256323 @default.
• W2237608905 cites W2163066856 @default.
• W2237608905 cites W2163709153 @default.
• W2237608905 cites W2166023752 @default.
• W2237608905 doi "https://doi.org/10.1111/bjh.13904" @default.
• W2237608905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26763986" @default.
• W2237608905 hasPublicationYear "2016" @default.
• W2237608905 type Work @default.
• W2237608905 sameAs 2237608905 @default.
• W2237608905 citedByCount "29" @default.
• W2237608905 countsByYear W22376089052016 @default.
• W2237608905 countsByYear W22376089052017 @default.
• W2237608905 countsByYear W22376089052018 @default.
• W2237608905 countsByYear W22376089052019 @default.
• W2237608905 countsByYear W22376089052020 @default.
• W2237608905 countsByYear W22376089052021 @default.
• W2237608905 countsByYear W22376089052022 @default.
• W2237608905 countsByYear W22376089052023 @default.
• W2237608905 crossrefType "journal-article" @default.
• W2237608905 hasAuthorship W2237608905A5016819589 @default.
• W2237608905 hasAuthorship W2237608905A5022006811 @default.
• W2237608905 hasAuthorship W2237608905A5025882756 @default.
• W2237608905 hasAuthorship W2237608905A5028386622 @default.
• W2237608905 hasAuthorship W2237608905A5046680192 @default.
• W2237608905 hasAuthorship W2237608905A5046704362 @default.
• W2237608905 hasAuthorship W2237608905A5047971271 @default.
• W2237608905 hasAuthorship W2237608905A5048088301 @default.
• W2237608905 hasAuthorship W2237608905A5049017377 @default.
• W2237608905 hasAuthorship W2237608905A5058392949 @default.
• W2237608905 hasAuthorship W2237608905A5066201212 @default.
• W2237608905 hasAuthorship W2237608905A5066452460 @default.
• W2237608905 hasAuthorship W2237608905A5069571388 @default.
• W2237608905 hasAuthorship W2237608905A5069596141 @default.
• W2237608905 hasAuthorship W2237608905A5071466957 @default.
• W2237608905 hasAuthorship W2237608905A5076114231 @default.
• W2237608905 hasAuthorship W2237608905A5078492047 @default.
• W2237608905 hasBestOaLocation W22376089051 @default.
• W2237608905 hasConcept C126322002 @default.
• W2237608905 hasConcept C141071460 @default.
• W2237608905 hasConcept C168563851 @default.
• W2237608905 hasConcept C207103383 @default.
• W2237608905 hasConcept C2776305933 @default.
• W2237608905 hasConcept C2776694085 @default.
• W2237608905 hasConcept C2776755627 @default.
• W2237608905 hasConcept C2777132456 @default.
• W2237608905 hasConcept C2778336483 @default.
• W2237608905 hasConcept C2779112685 @default.
• W2237608905 hasConcept C2779429289 @default.
• W2237608905 hasConcept C2780739268 @default.
• W2237608905 hasConcept C2780964509 @default.
• W2237608905 hasConcept C2781413609 @default.
• W2237608905 hasConcept C44249647 @default.
• W2237608905 hasConcept C71924100 @default.
• W2237608905 hasConceptScore W2237608905C126322002 @default.
• W2237608905 hasConceptScore W2237608905C141071460 @default.
• W2237608905 hasConceptScore W2237608905C168563851 @default.
• W2237608905 hasConceptScore W2237608905C207103383 @default.

• next